Please contact us for more information or to learn if you are eligible to participate.
The primary objective of this study is to demonstrate that the efficacy of Afrezza is noninferior to RAA injections, when both are in combination with a basal insulin, as measured by the change in HbA1c from baseline to Week 26 in pediatric subjects ≥4 and <18 years of age with T1DM or T2DM.
Surya N. Mulukutla, MD
Luis Cantu Jr.
Type of Trial